Compare BridgeBio Pharma Inc (BBIO) vs Global X Cloud Computing ETF (CLOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Global X Cloud Computing ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Global X Cloud Computing ETF trades at $27.93. The key difference: Global X Cloud Computing ETF is trading nearer its 52-week high, BridgeBio Pharma Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | CLOU | |
|---|---|---|
Market Cap | $16.61B | — |
Sector | Health | Sector/Thematic |
52-Week High | $90.17 | $28.09 |
52-Week Low | $47.29 | $17.60 |
Enterprise Value | $18.16B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
CLOU, the Global X Cloud Computing ETF, trades at $27.28, up 3.88% in the past 24 hours. Technical indicators show a bullish trend with strong moving average support, though RSI levels suggest potential overbought conditions. Recent news highlights long-term growth prospects driven by cloud computing expansion beyond AI, with top holdings like Snowflake and Datadog showing resilience.
The outlook for CLOU remains positive due to sector tailwinds and diversified cloud exposure, but risks include market volatility and competition from European tech initiatives. Investors should weigh growth potential against valuation concerns in the tech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Global X Cloud Computing ETF
CLOU is a thematic ETF that invests in companies leading the cloud revolution. It targets providers of SaaS, PaaS, and IaaS, including major firms like Salesforce, Akamai, and Shopify that drive modern digital infrastructure.
Read more on CLOU →
